Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 5/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ULK1 | O75385 | 1/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.35 |
| ▸ | BUB1 | O43683 | 1/20 | 0.35 |
| ▸ | PRKACG | P22612 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | ACSL5 | Q9ULC5 | 1/20 | 0.35 |
| ▸ | STK24 | Q9Y6E0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19705941 | 0.84 | GPBAR1 (0.43) | GPBAR1PPARDMRGPRX4MAPK14KDM4E | |
| SCHEMBL19698930 | 0.83 | GPBAR1 (0.40) | GPBAR1PPARDMRGPRX4MAPK14KDM4E | |
| SCHEMBL19738283 | 0.83 | GPBAR1 (0.42) | GPBAR1PPARDMRGPRX4MAPK14KDM4E | |
| SCHEMBL19725195 | 0.82 | GPBAR1 (0.40) | GPBAR1PPARDMRGPRX4MAPK14KDM4E | |
| SCHEMBL19705741 | 0.81 | KDM4E (0.45) | KDM4E | |
| SCHEMBL24565981 | 0.80 | GPBAR1 (0.39) | GPBAR1PPARDMRGPRX4MAPK14KDM4E | |
| SCHEMBL19705749 | 0.78 | GPBAR1 (0.38) | GPBAR1PPARDMRGPRX4MAPK14KDM4E | |
| SCHEMBL19705733 | 0.77 | EGLN1 (0.43) | KDM4EATM | |
| SCHEMBL26124336 | 0.76 | KDM4E (0.45) | KDM4ESCN9AHDAC1 | |
| SCHEMBL15601900 | 0.76 | GPBAR1 (0.42) | GPBAR1MRGPRX4KDM4ETLR7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10981881-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2021-04-20 | — | — | US | disclosed |
| US-20200369632-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2020-11-26 | — | — | US | disclosed |
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | GILEAD SCIENCES, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| EP-3257847-A1 | FXR (NR1H4) MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190308962-A1 | FXR (NR1H4) Modulating Compounds | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885MRGPRX4 278/4885 |
| US-10981881-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885MRGPRX4 296/4885 |
| US-20170355685-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885MRGPRX4 296/4885 |
| US-20200369632-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | GPBAR1 5/4885PPARD 42/4885MRGPRX4 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.